CRANBURY, N.J., Aug. 30 /PRNewswire-FirstCall/ -- Palatin Technologies,
Inc. (Amex: PTN) today announced that executive management will present at
the Roth Capital Partners 2006 New York Conference on Wednesday, September
6, 2006 at 4:30 p.m. EDT at The Westin New York at Times Square, New York,
NY and the Thomas Weisel Partners Healthcare Conference 2006 on Friday,
September 8, 2006 at 11:30 a.m. EDT at the Four Seasons Boston, Boston, MA.
Both presentations will be webcast live and can be accessed by logging
on to the investors section of Palatin Technologies website at
http://www.palatin.com on the day of the event. A replay of the
presentations will also be available on the company's website.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on
discovering and developing targeted, receptor-specific small molecule and
peptide therapeutics. The Company's lead product candidate, bremelanotide,
is currently in Phase II clinical trials for both male and female sexual
dysfunction. The Company's internal research and development capabilities,
anchored by its proprietary MIDAS(TM) technology, are fueling product
development. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders in order to maximize their
commercial potential. To date, the Company has formed partnerships with
Tyco Healthcare Mallinckrodt and King Pharmaceuticals. For additional
information regarding Palatin, please visit Palatin Technologies' website
at http://www.palatin.com.
Forward-looking Statements
Statements about the Company's future expectations, including
statements about its development programs, proposed indications for its
product candidates, pre-clinical activities, marketing collaborations, and
all other statements in this document other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934
and as that term is defined in the Private Securities Litigation Reform Act
of 1995. The Company intends that such forward-looking statements be
subject to the safe harbors created thereby. Palatin's actual results may
differ materially from those discussed in the forward-looking statements
for various reasons, including, but not limited to the Company's ability to
fund development of its technology, ability to establish and successfully
complete clinical trials and pre-clinical studies and the results of those
trials and studies, dependence on its partners for certain development
activities, need for regulatory approvals and commercial acceptance of its
products, ability to recommence marketing and gain commercial acceptance of
NeutroSpec(R) and ability to protect its intellectual property, and other
factors discussed in the Company's periodic filings with the Securities and
Exchange Commission. The Company is not responsible for updating for events
that occur after the date of this press release.
SOURCE Palatin Technologies, Inc.
 back to top
Related links:
http://www.palatin.com
CONTACT:
For Palatin Technologies: Stephen T. Wills,
CPA, MST, EVP-Operations / Chief Financial Officer,
+1-609-495-2200, info@palatin.com; For Institutional Investors
and Media: Carney Duntsch of Burns McClellan, +1-212-213-0006,
cduntsch@burnsmc.com
|
